Pulmatrix, Inc. stock is up 15.73% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 March’s closed higher than February.
Pulmatrix, Inc. discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology. Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis, and in patients with cystic fibrosis, is in Phase 1b clinical trials.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!